- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05573035
A Study to Investigate LYL845 in Adults With Solid Tumors
January 22, 2024 updated by: Lyell Immunopharma, Inc.
A Phase 1 Study to Assess the Safety and Efficacy of LYL845 in Adults With Relapsed and/or Refractory Metastatic or Locally Advanced Melanoma and Selected Solid Tumor Malignancies
This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in participants with relapsed or refractory (R/R) metastatic or locally advanced melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in participants with relapsed or refractory (R/R) metastatic or locally advanced melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).
During the dose-escalation phase of the study (Part A), participants with melanoma will be enrolled.
Once a safe recommended Phase 2 dose range (RP2DR) has been established in Part A, enrollment will be expanded (Part B) to include additional participants with melanoma, NSCLC and CRC.
Study Type
Interventional
Enrollment (Estimated)
108
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lauren Levine, MD
- Phone Number: 888-707-7917
- Email: clinicaltrials@lyell.com
Study Locations
-
-
California
-
Sacramento, California, United States, 95817
- Recruiting
- UC Davis Coomprehensive Cancer Center
-
Contact:
- Laura Molnar
- Phone Number: 916-734-3089
-
Principal Investigator:
- Naseem Esteghamat, MD
-
Santa Monica, California, United States, 90404
- Recruiting
- UCLA Medical Center
-
Contact:
- J. Randolph Hecht, MD
-
Contact:
- Chris Hannigan
- Email: CHannigan@mednet.ucla.edu
-
-
Connecticut
-
New Haven, Connecticut, United States, 06511
- Recruiting
- Yale Cancer Center, Yale University
-
Contact:
- Jialing Zhang
- Email: jialing.zhang@yale.edu
-
Contact:
- Michael Hurwitz, MD, PhD
- Email: michael.hurwitz@yale.edu
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Recruiting
- Georgetown University
-
Contact:
- Geoffrey Gibney, MD
-
Contact:
- Stephanie Wagner
- Phone Number: 202-687-9782
- Email: sw1095@georgetown.edu
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Recruiting
- University of Iowa Hospitals and Clinics
-
Contact:
- Asad Javed, MD
- Phone Number: 319-356-4200
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
Contact:
- Donald Lawrence, MD
- Email: dplawrence@mgh.harvard.edu
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Recruiting
- Hackensack Meridian Health Inc
-
Contact:
- Martin Gutierrez, MD
- Phone Number: 551-996-5499
-
Contact:
- Celina Joco
- Email: celina.joco@hmhn.org
-
New Brunswick, New Jersey, United States, 08901
- Recruiting
- Rutgers Cancer Institute of New Jersey
-
Contact:
- Sarah Weiss
- Email: saweiss@cinj.rutgers.edu
-
Contact:
- Xiaoru Chen
- Email: xc194@cinj.rutgers.edu
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Recruiting
- Duke University Medical Center
-
Contact:
- Brent Hanks, MD
-
Contact:
- CCI Clinical Trials Office
- Phone Number: (919) 681-6468
- Email: CCI-TrialReferrals@duke.edu
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Recruiting
- Ohio State University Medical Center
-
Contact:
- Cara Dauch
- Email: Cara.dauch@osumc.edu
-
Contact:
- Joal Beane, MD
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Recruiting
- Oregon Health Sciences University
-
Contact:
- Clinical Trials Line
- Phone Number: 503-494-1080
- Email: trials@ohsu.edu
-
Principal Investigator:
- Robert Eil
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15212
- Recruiting
- Allegheny General Hospital
-
Contact:
- Yazan Samhouri, MD
- Phone Number: 412-330-6151
- Email: clinicaltrials@ahn.org
-
-
Texas
-
Dallas, Texas, United States, 75235
- Recruiting
- University of Texas Southwestern Medical Center
-
Contact:
- Sanjay Chandrasekaran, MD
- Email: Sanjay.Chandrasekaran@UTSouthwestern.edu
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Recruiting
- Huntsman Cancer Institute at University of Utah
-
Contact:
- John Hyngstrom, MD
-
Contact:
- Kaitlin Stephens
- Phone Number: 801-213-8494
-
-
Washington
-
Seattle, Washington, United States, 98109
- Recruiting
- Fred Hutchinson Cancer Center
-
Contact:
- Fred Hutch Intake
- Phone Number: 206-606-1024
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age ≥ 18 years up to ≤ 75 years at the time of informed consent
- Confirmed diagnosis of melanoma, non-small cell lung cancer (NSCLC), or colorectal cancer (CRC) that is metastatic or locally advanced or unresectable and is relapsed and/or refractory (R/R) after standard therapy for each tumor histology
- Participants must have received prior systemic treatment for their metastatic disease or locally advanced disease based on tumor type as follows:
- Melanoma: participants with disease progression following an immune checkpoint inhibitor (CPI)
- NSCLC: participants with disease progression following at least 1 approved systemic therapy, including an immune CPI-containing regimen for appropriate patients or an approved targeted therapy for known molecular abnormalities if applicable to their disease
- CRC: participants with disease progression following at least 1 line of therapy, including a fluoropyrimidine with oxaliplatin or irinotecan. Microsatellite instability (MSI) high/mismatch repair deficient (dMMR) CRC participants must have disease progression following systemic therapy with immune CPIs.
- Measurable disease including at least 1 lesion that is safely resectable AND a target lesion to measure response and an additional lesion for biopsy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate organ and marrow function
- Women of childbearing potential must have a negative pregnancy test at screening
- All participants must agree to practice highly effective methods of contraception
- Fully recovered from toxicity from prior systemic anticancer therapy
Exclusion Criteria:
- Prior treatment with adoptive cellular therapy
- Prior solid organ transplantation
- Central nervous system (CNS) involvement of disease that is extensive, symptomatic or untreated, or patients with leptomeningeal disease
- Uncontrolled or symptomatic pleural effusion or ascites
- Untreated or active systemic infection
- Active autoimmune disease requiring treatment or primary immunodeficiency syndrome
- Systemic corticosteroids at a dose of >10 mg of prednisone or equivalent per day
- Other primary malignancy within 3 years prior to enrollment
- Impaired cardiac function or clinically significant cardiovascular disease
- Required chronic anticoagulation, such as warfarin, low molecular weight heparin, or Factor Xa inhibitors
- Pregnant or nursing (lactating) women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental LYL845
Epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy
|
LYL845 is an autologous tumor infiltrating lymphocyte (TIL) enhanced via Epi-R, a proprietary epigenetic reprogramming technology
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment-emergent adverse events (TEAEs)
Time Frame: Up to 2 years
|
Evaluate incidence of treatment-emergent adverse events (TEAEs)
|
Up to 2 years
|
Severity of treatment-emergent adverse events (TEAEs)
Time Frame: Up to 2 years
|
Evaluate severity of treatment-emergent adverse events (TEAEs)
|
Up to 2 years
|
Determine recommended Phase 2 Dose Range (RP2DR)
Time Frame: Up to 2 years
|
Determine the recommended Phase 2 dose range (during dose-escalation phase)
|
Up to 2 years
|
Incidence of dose-limiting toxicities (DLTs)
Time Frame: Up to 28 days
|
Evaluate incidence of dose-limiting toxicities (DLTs)
|
Up to 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate (ORR) by RECIST, version 1.1
Time Frame: up to 2 years
|
Evaluate anti-tumor activity of LYL845 based on overall response rate (ORR) by RECIST, version 1.1
|
up to 2 years
|
Duration of response (DOR)
Time Frame: up to 2 years
|
Evaluate duration of response (DOR)
|
up to 2 years
|
Progression-free survival (PFS)
Time Frame: up to 2 years
|
Evaluate progression-free survival (PFS)
|
up to 2 years
|
Overall survival (OS)
Time Frame: up to 2 years
|
Evaluate overall survival (OS)
|
up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 19, 2022
Primary Completion (Estimated)
August 1, 2025
Study Completion (Estimated)
September 1, 2027
Study Registration Dates
First Submitted
October 6, 2022
First Submitted That Met QC Criteria
October 6, 2022
First Posted (Actual)
October 10, 2022
Study Record Updates
Last Update Posted (Actual)
January 24, 2024
Last Update Submitted That Met QC Criteria
January 22, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Lung Neoplasms
- Neuroendocrine Tumors
- Nevi and Melanomas
- Carcinoma, Non-Small-Cell Lung
- Colorectal Neoplasms
- Melanoma
Other Study ID Numbers
- LYL845-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RecruitingMetastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous MelanomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA MelanomaUnited States
-
MelanomaPRO, RussiaRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, OcularRussian Federation
-
National Cancer Institute (NCI)CompletedStage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC MelanomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA MelanomaUnited States
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
-
Emory UniversityGenentech, Inc.Active, not recruitingStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IVUnited States